Abatacept
S100 protein levels predict abatacept response in juvenile idiopathic arthritis
Lower levels of S100 proteins at baseline predict better treatment response with abatacept in patients with polyarticular-course juvenile idiopathic arthritis, according to data published in Arthritis Research & Therapy.
Blockade of T-Cell Costimulatory Pathways
VIDEO: ‘So much’ placebo power can be harnessed to treat rheumatology patients
In this Healio video exclusive, Leonard Calabrese, DO, chief medical editor of Healio Rheumatology, discussed the top items from the February issue, including an exploration of how the placebo effect can be applied in rheumatology.
‘Double negative’ B cells may predict abatacept response in rheumatoid arthritis
SCOTTSDALE, Ariz. — Patients with rheumatoid arthritis who had a decrease in a certain type of B cell that fails to express immunoglobulin D and CD27 saw clinical improvement with abatacept, according to data presented here.
Therapy choice in rheumatoid arthritis does not impact serious infection risk
Among patients with rheumatoid arthritis, the chosen course of therapy does not have an impact on the risk for developing a serious infection, according to data published in Rheumatology.
FDA expands approval of abatacept for children with psoriatic arthritis
The FDA has approved a supplemental biologics licensing application from Bristol Myers Squibb expanding the indication of abatacept to include children aged 2 years and older with psoriatic arthritis, according to a company press release.
Abatacept, certolizumab pegol superior to conventional therapy for rheumatoid arthritis
Patients with rheumatoid arthritis who receive abatacept or certolizumab pegol achieve clinical remission at higher rates than those receiving active conventional therapy, according to data published in Annals of the Rheumatic Diseases.
New trials, therapies to address unmet needs in ANCA-associated vasculitis
SAN DIEGO — The future of ANCA-associated vasculitis management appears promising, as upcoming therapies will likely address current unmet needs, according to a speaker at the 2023 Congress of Clinical Rheumatology West.
New ACR SSc-ILD guidelines warn against glucocorticoids as first-line therapy
The American College of Rheumatology “strongly recommends” against the use of glucocorticoids as a first-line therapy for interstitial lung disease in patients with systemic sclerosis-associated ILD, according to newly released guidelines.
VIDEO: Biggest challenges in RA treatment
In this video, John M. Davis, III, MD, clinical rheumatologist and professor of medicine at Mayo Clinic College of Medicine and Science, discussed some of the biggest challenges in treating rheumatoid arthritis, including issues with infections and other comorbidities.